CL2017003032A1 - Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste - Google Patents
Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de ésteInfo
- Publication number
- CL2017003032A1 CL2017003032A1 CL2017003032A CL2017003032A CL2017003032A1 CL 2017003032 A1 CL2017003032 A1 CL 2017003032A1 CL 2017003032 A CL2017003032 A CL 2017003032A CL 2017003032 A CL2017003032 A CL 2017003032A CL 2017003032 A1 CL2017003032 A1 CL 2017003032A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- pyrido
- pyrimidine derivative
- pyrimidine
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 2
- 159000000016 pyrido[3,4-d]pyrimidines Chemical class 0.000 title 1
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 abstract 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 abstract 1
- 239000002131 composite material Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
<p>EL PROPÓSITO DE LA PRESENTE INVENCIÓN ES PROPORCIONAR UN COMPUESTO QUE POSEE UNA EXCELENTE ACTIVIDAD INHIBIDORA DE CDK4/6. LA PRESENTE INVENCIÓN ES UN COMPUESTO REPRESENTADO POR LA FÓRMULA (I) O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015110684 | 2015-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017003032A1 true CL2017003032A1 (es) | 2018-03-09 |
Family
ID=57442335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017003032A CL2017003032A1 (es) | 2015-05-29 | 2017-11-29 | Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10124004B2 (es) |
| EP (1) | EP3305785B1 (es) |
| JP (1) | JP6400196B2 (es) |
| KR (1) | KR102601320B1 (es) |
| CN (1) | CN107614499B (es) |
| AR (1) | AR104789A1 (es) |
| AU (1) | AU2016272258B2 (es) |
| CA (1) | CA2987019C (es) |
| CL (1) | CL2017003032A1 (es) |
| CO (1) | CO2017012067A2 (es) |
| CY (1) | CY1124800T1 (es) |
| DK (1) | DK3305785T3 (es) |
| ES (1) | ES2893478T3 (es) |
| HR (1) | HRP20211360T1 (es) |
| HU (1) | HUE056996T2 (es) |
| IL (1) | IL255488B (es) |
| LT (1) | LT3305785T (es) |
| MX (1) | MX378648B (es) |
| MY (1) | MY192487A (es) |
| PH (1) | PH12017502171B1 (es) |
| PL (1) | PL3305785T3 (es) |
| PT (1) | PT3305785T (es) |
| RU (1) | RU2695337C2 (es) |
| SA (1) | SA517390409B1 (es) |
| SG (1) | SG11201709837RA (es) |
| SI (1) | SI3305785T1 (es) |
| TW (1) | TWI714590B (es) |
| WO (1) | WO2016194831A1 (es) |
| ZA (1) | ZA201707499B (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3041854C (en) | 2016-11-28 | 2025-05-13 | Teijin Pharma Limited | PYRIDO DERIVATIVE CRYSTAL [3,4-D]PYRIMIDINE OR ITS SOLVA |
| US11084814B2 (en) * | 2016-11-28 | 2021-08-10 | Teijin Pharma Limited | Pyrido[3, 4-d]pyrimidine derivative and pharmaceutically acceptable salt thereof |
| CN107337634B (zh) * | 2017-08-28 | 2019-07-09 | 新发药业有限公司 | 一种阿贝西利中间体化合物的制备方法 |
| US11440912B2 (en) | 2017-10-27 | 2022-09-13 | Fresenius Kabi Oncology Ltd | Process for the preparation of ribociclib and its salts |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| JP7569688B2 (ja) | 2017-12-22 | 2024-10-18 | ハイバーセル，インコーポレイテッド | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体 |
| US20220017520A1 (en) | 2018-12-19 | 2022-01-20 | Keythera (Suzhou) Pharmaceuticals Co. Ltd. | Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| AR119493A1 (es) * | 2019-07-29 | 2021-12-22 | Servier Lab | Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos |
| CN115942937B (zh) * | 2020-08-17 | 2025-07-25 | 浙江扬厉医药技术有限公司 | 嘧啶并环类化合物 |
| GB202018412D0 (en) * | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
| AR124154A1 (es) | 2020-11-27 | 2023-02-22 | Rhizen Pharmaceuticals Ag | Inhibidores de cdk |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| CN116023367A (zh) * | 2021-10-25 | 2023-04-28 | 优领医药科技(香港)有限公司 | 含四氢呋喃多环类衍生物、其药学上可接受的盐及其制备方法和应用 |
| AU2022412837A1 (en) * | 2021-12-16 | 2024-06-13 | Teijin Pharma Limited | Cdk9 inhibitor and use thereof |
| CN116410189B (zh) * | 2021-12-30 | 2024-08-06 | 中国科学院上海药物研究所 | 一种嘧啶并吡啶类化合物及其药用组合物和应用 |
| WO2023155841A1 (zh) * | 2022-02-16 | 2023-08-24 | 南京明德新药研发有限公司 | 嘧啶并环类化合物的盐型、晶型 |
| EP4558493A1 (en) * | 2022-07-18 | 2025-05-28 | Iambic Therapeutics, Inc. | Quinazoline compounds and methods of use |
| WO2024238574A1 (en) * | 2023-05-15 | 2024-11-21 | Aleksia Therapeutics, Inc. | Cdk inhibitor compounds |
| TW202521113A (zh) * | 2023-09-27 | 2025-06-01 | 日商帝人製藥股份有限公司 | 類風濕性關節炎治療藥 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101001857B (zh) | 2002-01-22 | 2011-06-22 | 沃尼尔·朗伯有限责任公司 | 2-(吡啶-2-基氨基)-吡啶并[2,3-d]嘧啶-7-酮 |
| DK1648889T3 (da) * | 2003-07-11 | 2009-01-05 | Warner Lambert Co | Isethionatsalt af en selektiv CDK4-inhibitor |
| WO2006008874A1 (ja) * | 2004-05-21 | 2006-01-26 | Banyu Pharmaceutical Co., Ltd. | アミノチアゾール骨格を有するＣｄｋ４，６選択的阻害剤 |
| US8685980B2 (en) | 2008-08-22 | 2014-04-01 | Novartis Ag | Pyrrolopyrimidine compounds and their uses |
| PA8852901A1 (es) | 2008-12-22 | 2010-07-27 | Lilly Co Eli | Inhibidores de proteina cinasa |
| UY33226A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
| GB201216017D0 (en) * | 2012-09-07 | 2012-10-24 | Cancer Rec Tech Ltd | Inhibitor compounds |
-
2016
- 2016-05-27 MY MYPI2017704377A patent/MY192487A/en unknown
- 2016-05-27 EP EP16803266.2A patent/EP3305785B1/en active Active
- 2016-05-27 DK DK16803266.2T patent/DK3305785T3/da active
- 2016-05-27 HR HRP20211360TT patent/HRP20211360T1/hr unknown
- 2016-05-27 ES ES16803266T patent/ES2893478T3/es active Active
- 2016-05-27 SI SI201631322T patent/SI3305785T1/sl unknown
- 2016-05-27 CA CA2987019A patent/CA2987019C/en active Active
- 2016-05-27 SG SG11201709837RA patent/SG11201709837RA/en unknown
- 2016-05-27 PT PT16803266T patent/PT3305785T/pt unknown
- 2016-05-27 AR ARP160101534A patent/AR104789A1/es active IP Right Grant
- 2016-05-27 US US15/577,802 patent/US10124004B2/en active Active
- 2016-05-27 PL PL16803266T patent/PL3305785T3/pl unknown
- 2016-05-27 WO PCT/JP2016/065770 patent/WO2016194831A1/ja not_active Ceased
- 2016-05-27 AU AU2016272258A patent/AU2016272258B2/en active Active
- 2016-05-27 KR KR1020177034478A patent/KR102601320B1/ko active Active
- 2016-05-27 HU HUE16803266A patent/HUE056996T2/hu unknown
- 2016-05-27 TW TW105116653A patent/TWI714590B/zh active
- 2016-05-27 MX MX2017015277A patent/MX378648B/es unknown
- 2016-05-27 RU RU2017141454A patent/RU2695337C2/ru active
- 2016-05-27 JP JP2017521910A patent/JP6400196B2/ja active Active
- 2016-05-27 CN CN201680033175.XA patent/CN107614499B/zh active Active
- 2016-05-27 LT LTEPPCT/JP2016/065770T patent/LT3305785T/lt unknown
-
2017
- 2017-11-06 ZA ZA2017/07499A patent/ZA201707499B/en unknown
- 2017-11-07 IL IL255488A patent/IL255488B/en active IP Right Grant
- 2017-11-25 SA SA517390409A patent/SA517390409B1/ar unknown
- 2017-11-28 CO CONC2017/0012067A patent/CO2017012067A2/es unknown
- 2017-11-29 CL CL2017003032A patent/CL2017003032A1/es unknown
- 2017-11-29 PH PH12017502171A patent/PH12017502171B1/en unknown
-
2021
- 2021-10-08 CY CY20211100878T patent/CY1124800T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017003032A1 (es) | Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste | |
| ECSP18093777A (es) | Derivados de pirazolopirimidina como inhibidor de quinasa | |
| MX2017006266A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos. | |
| BR112017019286A2 (pt) | composto de fórmula (i) ou um sal farmaceuticamente aceitável deste | |
| DOP2016000094A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4. | |
| ECSP20035590A (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| CO2019004034A2 (es) | Compuesto de piridina | |
| CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
| MX2016009230A (es) | Macrociclicos con grupos p2'heterociclicos como inhibidores del factor xia. | |
| EA201792021A1 (ru) | Ингибитор jak | |
| BR112016029825A2 (pt) | composto | |
| MX381970B (es) | Derivado de sulfonamida y composición farmacéutica que contiene el mismo. | |
| CL2019001419A1 (es) | Derivado de pirido[3,4–d]pirimidina y su sal farmacéuticamente aceptable. | |
| EA201790016A1 (ru) | АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K | |
| MX2018008307A (es) | Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk). | |
| CL2020000376A1 (es) | Compuesto pentacíclico. | |
| DOP2019000021A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| CO2019007836A2 (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| MX2018000677A (es) | Derivado de urea y uso del mismo. |